Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
0.5081
-0.0394 (-7.20%)
At close: Mar 28, 2025, 4:00 PM
0.5066
-0.0015 (-0.29%)
After-hours: Mar 28, 2025, 7:58 PM EDT
Veru Inc. Employees
Veru Inc. had 210 employees as of September 30, 2024. The number of employees increased by 21 or 11.11% compared to the previous year.
Employees
210
Change (1Y)
21
Growth (1Y)
11.11%
Revenue / Employee
$80,412
Profits / Employee
-$183,194
Market Cap
74.38M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VERU News
- 6 weeks ago - Veru Inc (VERU) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress - GlobeNewsWire
- 2 months ago - Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough - Benzinga
- 2 months ago - Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction - GlobeNewsWire
- 3 months ago - Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business - GlobeNewsWire
- 4 months ago - Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders - GlobeNewsWire
- 5 months ago - Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek - GlobeNewsWire
- 5 months ago - Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss - GlobeNewsWire